Overview

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Status:
Completed

Trial end date:
2017-06-20

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy in reducing glycated hemoglobin of ipragliflozin in combination with metformin compared with metformin plus placebo in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Europe B.V.

Treatments:

Ipragliflozin
Metformin